KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Treasury Shares (2019 - 2025)

Historic Treasury Shares for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $20.0 million.

  • GoodRx Holdings' Treasury Shares fell 430.62% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.0 million, marking a year-over-year decrease of 430.62%. This contributed to the annual value of $20.9 million for FY2024, which is 7416.67% up from last year.
  • GoodRx Holdings' Treasury Shares amounted to $20.0 million in Q3 2025, which was down 430.62% from $20.0 million recorded in Q2 2025.
  • In the past 5 years, GoodRx Holdings' Treasury Shares registered a high of $20.9 million during Q1 2024, and its lowest value of $1.1 million during Q3 2023.
  • In the last 5 years, GoodRx Holdings' Treasury Shares had a median value of $8.5 million in 2022 and averaged $11.4 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first plummeted by 8762.83% in 2023, then surged by 173655.54% in 2024.
  • GoodRx Holdings' Treasury Shares (Quarter) stood at $5.6 million in 2021, then surged by 49.8% to $8.5 million in 2022, then skyrocketed by 41.91% to $12.0 million in 2023, then skyrocketed by 74.17% to $20.9 million in 2024, then decreased by 4.31% to $20.0 million in 2025.
  • Its last three reported values are $20.0 million in Q3 2025, $20.0 million for Q2 2025, and $20.0 million during Q1 2025.